ArticleVirology journal2019
Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
Article in Virology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Cost-effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV-positive women in cervical cancer screening.International journal of cancer · 2026Article
- HPV testing alone as a test of cure after treatment with cervical loop excision: a retrospective register-based cohort study.Infectious agents and cancer · 2025Article
- Novel diagnostics for improved treatment of gynecological cancer.Upsala journal of medical sciences · 2025Review
- History of HPV in HPV-positive elderly women.European journal of obstetrics & gynecology and reproductive biology: X · 2024Article
- Compositional and functional differences of the vaginal microbiota of women with and without cervical dysplasia.Scientific reports · 2024Article
- Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid.iScience · 2024Article
- Incidence of oncogenic HPV and HPV-related dysplasia five years after a negative HPV test by self-sampling in elderly women.Infectious agents and cancer · 2022Article
- Cervical Cancer Prophylaxis-State-of-the-Art and Perspectives.Healthcare (Basel, Switzerland) · 2022Review
- Metabolomic Laboratory-Developed Tests: Current Status and Perspectives.Metabolites · 2021Review
- Article
- An evaluation of solid versus liquid transport media for high-risk HPV detection and cervical cancer screening on self-collected specimens.Infectious agents and cancer · 2020Article
- Temporal changes in the vaginal microbiota in self-samples and its association with persistent HPV16 infection and CIN2.Virology journal · 2020Article
- Acceptability of self- collection for human papillomavirus detection in the Eastern Cape, South Africa.PloS one · 2020Article
- Article
- HPV viral load in self-collected vaginal fluid samples as predictor for presence of cervical intraepithelial neoplasia.Virology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe indicating FTA card is a dry medium used for collection of cervical samples. HPVIR is a multiplex real-time PCR test that detects 12 high-risk human papillomavirus types (hrHPV) and provides single genotype information for HPV16, - 31, - 35, - 39, - 51, - 56, and - 59 and pooled type information for HPV18/45 and HPV33/52/58. The aim of this study was to evaluate whether a strategy with cervical samples collected on the FTA card and subsequently analysed with the HPVIR test complies with the criteria of the international guidelines for a clinically validated method for cervical screening.
methodsWe performed a non-inferiority test comparing the clinical sensitivity and specificity of the candidate test (FTA card and HPVIR) with a clinically validated reference test (Cobas
resultsThe clinical sensitivity and specificity for samples collected on the FTA card and analysed using the HPVIR test were non-inferior to samples analysed with the Cobas® HPV test based on LBC samples (non-inferiority test score, p = 1.0 × 10
conclusionsSamples collected on the indicating FTA card and analysed with HPVIR test fulfil the requirements of the international guidelines and can therefore be used in primary cervical cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.